María A Martín-Martínez1, Santos Castañeda2,3, Fernando Sánchez-Alonso1, Carmen García-Gómez4, Carlos González-Juanatey5, Jesús T Sánchez-Costa1, María A Belmonte-López6, Jesús Tornero-Molina7, José Santos-Rey8, Carmen O Sánchez González9, Estefanía Quesada10, María P Moreno-Gil11, Tatiana Cobo-Ibáñez12, José A Pinto-Tasnde13, Jesús Babío-Herráez14, Gema Bonilla15, Antonio Juan-Mas16, Francisco J Manero-Ruiz17, Montserrat Romera-Baurés18, Javier Bachiller-Corral19, Eugenio Chamizo-Carmona20, Mirem Uriarte-Ecenarro2, Carmen Barbadillo21, Cristina Fernández-Carballido22, Elena Aurrecoechea23, Ingrid Möller-Parrera24, Javier Llorca25, Miguel A González-Gay26,27,28. 1. Research Unit of Spanish Society of Rheumatology, Madrid, Spain. 2. Division of Rheumatology, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain. 3. Cátedra UAM-ROCHE, EPID-Future, Universidad Autónoma de Madrid (UAM), Madrid, Spain. 4. Division of Rheumatology, Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain. 5. Division of Cardiology, Hospital Lucus Augusti, Lugo, Spain. 6. Division of Rheumatology, Hospital General Carlos Haya, Málaga, Spain. 7. Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain. 8. Division of Rheumatology, Hospital Virgen de la Salud, Toledo, Spain. 9. Division of Rheumatology, Hospital del Sureste, Madrid, Spain. 10. Division of Rheumatology, Hospital Universitario Vall D'Hebron, Barcelona, Spain. 11. Division of Rheumatology, Complejo Hospitalario de Cáceres, Cáceres, Spain. 12. Division of Rheumatology, Hospital Universitario Infanta Sofía, Madrid, Spain. 13. Division of Rheumatology, Complejo Hospitalario Universitario A Coruña, Spain. 14. Division of Rheumatology, Hospital de Cabueñes, Asturias, Spain. 15. Division of Rheumatology, Hospital Universitario de La Paz, Madrid, Spain. 16. Division of Rheumatology, Hospital Sont Llatzer, Palma de Mallorca, Spain. 17. Division of Rheumatology, Hospital Universitario Miguel Servet, Zaragoza, Spain. 18. Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain. 19. Division of Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain. 20. Division of Rheumatology, Hospital de Mérida, Badajoz, Spain. 21. Division of Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain. 22. Division of Rheumatology, Hospital General de Elda, Alicante, Spain. 23. Division of Rheumatology, Hospital U. Sierrallana, Torrelavega, Santander, Spain. 24. Division of Rheumatology, Instituto Poal, Barcelona, Spain. 25. Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain. 26. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 27. Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain, Spain. 28. School of Physiology, Faculty of Health Sciences, Cardiovascular Pathophysiology and Genomics Research Unit, University of the Witwatersrand, South Africa.
Abstract
OBJECTIVES: To determine cardiovascular (CV) mortality and incidence of the first CV event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-up. METHODS: This is an analysis of the CARdiovascular in rheMAatology (CARMA) study after 5 years of follow-up. It includes patients with RA (n = 775), AS (n = 738) and PsA (n = 721), and individuals without CIRD (n = 677) attending outpatient rheumatology clinics from 67 public hospitals in Spain. Descriptive analyses were performed for the CV mortality at 5 years. The Systematic COronary Risk Evaluation (SCORE) function at 5 years was calculated to determine the expected risk of CV mortality. Poisson models were used to estimate the incidence rates of the first CVE. Hazard ratios of the risk factors involved in the development of the first CVE were evaluated using the Weibull proportional hazard model. RESULTS: Overall, 2382 subjects completed the follow-up visit at 5 years. Fifteen patients died due to CVE. CV deaths observed in the CIRD cohort were lower than that predicted by SCORE risk charts. The highest incidence rate of CVE [7.39 cases per 1000 person-years (95% CI 4.63, 11.18)] was found in PsA patients. However, after adjusting for age, sex and CV risk factors, AS was the inflammatory disease more commonly associated with CVE at 5 years [hazard ratio 4.60 (P =0.02)], compared with those without CIRD. CONCLUSIONS: Cardiovascular mortality in patients with CIRD at 5 years of follow-up is lower than estimated. Patients with AS have a higher risk of developing a first CVE after 5 years of follow-up.
OBJECTIVES: To determine cardiovascular (CV) mortality and incidence of the first CV event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD) after 5 years of follow-up. METHODS: This is an analysis of the CARdiovascular in rheMAatology (CARMA) study after 5 years of follow-up. It includes patients with RA (n = 775), AS (n = 738) and PsA (n = 721), and individuals without CIRD (n = 677) attending outpatient rheumatology clinics from 67 public hospitals in Spain. Descriptive analyses were performed for the CV mortality at 5 years. The Systematic COronary Risk Evaluation (SCORE) function at 5 years was calculated to determine the expected risk of CV mortality. Poisson models were used to estimate the incidence rates of the first CVE. Hazard ratios of the risk factors involved in the development of the first CVE were evaluated using the Weibull proportional hazard model. RESULTS: Overall, 2382 subjects completed the follow-up visit at 5 years. Fifteen patientsdied due to CVE. CV deaths observed in the CIRD cohort were lower than that predicted by SCORE risk charts. The highest incidence rate of CVE [7.39 cases per 1000 person-years (95% CI 4.63, 11.18)] was found in PsA patients. However, after adjusting for age, sex and CV risk factors, AS was the inflammatory disease more commonly associated with CVE at 5 years [hazard ratio 4.60 (P =0.02)], compared with those without CIRD. CONCLUSIONS: Cardiovascular mortality in patients with CIRD at 5 years of follow-up is lower than estimated. Patients with AS have a higher risk of developing a first CVE after 5 years of follow-up.
Authors: Hye Sang Park; Ana Laiz; Petra Díaz Del Campo; María A Martín Martínez; M Guerra-Rodriguez; Concepcion Alonso-Martin; Jesus Sanchez-Vega; Hector Corominas Journal: Front Med (Lausanne) Date: 2022-03-25
Authors: Lin-Hong Shi; Steven H Lam; Ho So; Edmund K Li; Tena K Li; Cheuk-Chun Szeto; Lai-Shan Tam Journal: Ther Adv Musculoskelet Dis Date: 2022-09-08 Impact factor: 3.625